A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

Completed · Phase 3

Conditions studied: Prostate Cancer

In brief

Participants who completed the FE200486 CS21 study (NCT00295750) could enter the FE200486 CS21A study. The study continued until all non-discontinued participants had received treatment for at least 5 years.

Key facts

Study ID
NCT00451958
Run by
Ferring Pharmaceuticals
People needed
386
Starts
2007-03-01
Expected to finish
2011-12-01
Last updated by the study team
2013-03-21

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.